TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07287098: preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Sponsor: Eli Lilly and Company · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$12,150,600

Rescue Site Savings

+$8,038,800

Unlock Full NCT07287098 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07287098 Rescue Dossier →